Andrea L. Kossler

Ophthalmology

2452 Watson Ct
Palo Alto, CA 94303

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

WSOPRAS and ITEDS Consensus Statement on the Assessment and Management of Thyroid Eye Disease.

WSOPRAS and ITEDS Consensus Statement on the Assessment and Management of Thyroid Eye Disease.

Journal: Ophthalmic plastic and reconstructive surgery

Published: September 02, 2026

The Role of Systemic Methotrexate on Preventing Proliferative Vitreoretinopathy Following Retinal Detachment Repair.

The Role of Systemic Methotrexate on Preventing Proliferative Vitreoretinopathy Following Retinal Detachment Repair.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: May 15, 2026

Risk of Retinal Redetachment After Cataract Surgery Following Retinal Detachment Repair in Myopic and Highly Myopic Eyes.

Risk of Retinal Redetachment After Cataract Surgery Following Retinal Detachment Repair in Myopic and Highly Myopic Eyes.

Journal: Journal of vitreoretinal diseases

Published: February 27, 2026

Primary hypertrophic osteoarthropathy presenting with ptosis and floppy eyelids: a review of ophthalmic manifestations, histopathology, and pathophysiology.

Primary hypertrophic osteoarthropathy presenting with ptosis and floppy eyelids: a review of ophthalmic manifestations, histopathology, and pathophysiology.

Journal: Orbit (Amsterdam, Netherlands)

Published: February 20, 2026

A rare case of orbital desmoid-type fibromatosis treated with cryoablation: case report and literature review.

A rare case of orbital desmoid-type fibromatosis treated with cryoablation: case report and literature review.

Journal: Orbit (Amsterdam, Netherlands)

Published: February 17, 2026

Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease.

Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease.

Journal: Communications medicine

Published: February 02, 2026

THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.

THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.

Journal: Ophthalmology

Published: February 02, 2026

Teprotumumab associated menstrual changes.

Teprotumumab associated menstrual changes.

Journal: Orbit (Amsterdam, Netherlands)

Published: January 13, 2026

Corticosteroids Versus Teprotumumab for the Treatment of Thyroid Eye Disease. Does Either Mitigate the Need for Additional Treatments?

Corticosteroids Versus Teprotumumab for the Treatment of Thyroid Eye Disease. Does Either Mitigate the Need for Additional Treatments?

Journal: Thyroid : official journal of the American Thyroid Association

Published: December 30, 2025

Reply to Comment on Ocular and Orbital Trauma Correlated With an Increased Risk of Mortality in Female Patients With a History of Intimate Partner Violence.

Reply to Comment on Ocular and Orbital Trauma Correlated With an Increased Risk of Mortality in Female Patients With a History of Intimate Partner Violence.

Journal: American journal of ophthalmology

Published: November 10, 2025

IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.

IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.

Journal: Scientific reports

Published: October 21, 2025

The Efficacy and Safety of Teprotumumab in Geriatrics Patients: A Multicenter Study.

The Efficacy and Safety of Teprotumumab in Geriatrics Patients: A Multicenter Study.

Journal: Ophthalmic plastic and reconstructive surgery

Published: September 10, 2025

Showing 1-12 of 109

Last Updated: 09/26/2026